PURPOSE: The use of @entity750 5- @entity750 type 3 receptor antagonists has substantially reduced, but not eliminated, @entity390 and @entity391 in @entity5 chemotherapy. This study sought to investigate whether efficacy of antiemetic treatment with @entity3974 and @entity19473 depends on @entity5320 ( @entity5320 ) genotype, hypothesizing that the rapid and particularly the ultrarapid metabolizers of these drugs are at risk of being undertreated. @entity1 AND METHODS: Included in the study were 270 @entity5 @entity1 receiving their first day of chemotherapy. @entity390 and @entity391 were documented using standardized interviews. The intensity of @entity390 was measured with visual analog scales before and twice during the chemotherapy. The relationship between the @entity5320 genotypes and the @entity19473 serum concentrations 3 and 6 hours after drug administration was analyzed in a subgroup of 42 @entity1 . @entity5320 genotyping was carried out by polymerase chain reaction-restriction fragment length polymorphism analysis. RESULTS: Genetically defined poor metabolizers had higher serum concentrations of @entity19473 than all other @entity1 (P <.03). Approximately 30% of all @entity1 receiving chemotherapy experienced @entity390 and @entity391 . Genetically defined ultrarapid meta-bolizers of @entity5320 substrates had @entity391 within the first 4 hours (P <.001) and within the period 5 to 24 hours (P <.03) after treatment than all the other @entity1 ; the tendency for @entity390 was similar. This difference was more pronounced in @entity1 treated with @entity19473 than in those treated with @entity3974 . CONCLUSION: Antiemetic treatment with @entity19473 or @entity3974 could be improved by adjustment for the @entity5320 genotype; approximately 50 subjects would have to be genotyped to protect one @entity1 from severe @entity391 .

Patient-tailored antiemetic treatment with XXXX type 3 receptor antagonists according to @entity5320 genotypes.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity3974 :: ('MESH:D017294', 'Chemical') :: ['ondansetron'] @entity390 :: ('MESH:D009325', 'Disease') :: ['Nausea', 'nausea'] @entity5320 :: ('1565', 'Gene') :: ['CYP2D6', 'cytochrome P-450 2D6'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting', 'higher frequency of vomiting', 'emesis'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin', 'hydroxytryptamine'] @entity19473 :: ('MESH:C045504', 'Chemical') :: ['tropisetron']
@entity750 :: (MESH:D012701,Chemical) :: ['5-hydroxytryptamine']
